Sep 9, 2025, 06:52
Jordi Remon: CT+IO Remains Standard of Care for NSCLC While New Agents are Awaited
Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Patients with NSCLC and asymptomatic brain mets, is a poor prognosis population.
The intensification of 1st line with addition antiCA4 drug (Nivo+Ipi+2 cycles CT like CheckMate9LA) did not reached primary endpoint in NIVIPI-Brain trial. CT+IO remains SoC and new agents are awaited.”
More posts featuring NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 17:59
Sep 9, 2025, 17:43
Sep 9, 2025, 16:51
Sep 9, 2025, 15:59
Sep 9, 2025, 15:49